PMR

Amazon steps up healthcare efforts with $5 monthly subscription

Jan 24 (Reuters) – Amazon.com Inc (AMZN.O) said on Tuesday it is offering a $5 monthly subscription plan to US Prime members that will cover a range of generic drugs and their home delivery, bolstering the e-commerce giant’s push into healthcare. . The program, named RxPass, includes more than 50 drugs that treat more than …

Amazon steps up healthcare efforts with $5 monthly subscription Read More »

Wall St stumbles after weak data, hawkish Fed comments

Fed’s Bullard and Mester raise return rates U.S. retail sales tumble in December Indices down: Dow 1.28%, S&P 1.07%, Nasdaq 0.78% Jan 18 (Reuters) – Major Wall Street indexes fell on Wednesday after weak economic data and hawkish comments from Federal Reserve officials raised concerns that the central bank will not suspend interest rate hikes …

Wall St stumbles after weak data, hawkish Fed comments Read More »

Eisai and Biogen Receive US FDA Approval for Alzheimer’s Drug and Seek Full Approval

Jan 7 (Reuters) – The U.S. Food and Drug Administration on Friday approved Alzheimer’s disease drug lecanemab, developed by Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) for patients in the early stages of mind sickness. Eisai and Biogen said on Saturday that the Japanese drugmaker had sought full FDA approval for the drug. The …

Eisai and Biogen Receive US FDA Approval for Alzheimer’s Drug and Seek Full Approval Read More »

Exclusive: China in talks with Pfizer for generic COVID drug

HONG KONG/BEIJING, Jan 6 (Reuters) – China is in talks with Pfizer Inc for a license that will allow domestic drugmakers to manufacture and distribute a generic version of the COVID-19 antiviral drug of US company Paxlovid in China, three sources told Reuters. China’s medical products regulator – the National Medical Products Administration (NMPA) – …

Exclusive: China in talks with Pfizer for generic COVID drug Read More »

Congress report: US FDA broke its own protocols by approving Biogen Alzheimer’s drug

WASHINGTON, Dec 29 (Reuters) – The U.S. Food and Drug Administration failed to follow its own internal guidelines and practices during the approval process for Biogen’s (BIIB.O) drug Aduhelm for Alzheimer’s disease , which was “plagued by irregularities,” according to a congressional report. presented Thursday. The FDA’s interactions with Biogen were “atypical” and did not …

Congress report: US FDA broke its own protocols by approving Biogen Alzheimer’s drug Read More »

Wall St closes slightly higher after four days of selling

BOJ policy change rattles global sentiment Tesla drops 8% after brokers cut PT Energy stocks lead gains on crude support Indices up: Dow 0.28%, S&P 0.10%, Nasdaq 0.01% Dec 20 (Reuters) – Wall Street closed slightly higher on Tuesday after four sessions of declines, but investors worried about weak holiday buying and rising bond yields …

Wall St closes slightly higher after four days of selling Read More »

Wall Street falls for fourth straight day as recession worries overnight

Dec 19 (Reuters) – Wall Street stocks closed lower on Monday for a fourth straight session, with the Nasdaq leading the declines as investors shun riskier bets amid fears the Federal Reserve’s tightening campaign could take a dive the US economy in a recession. The three major U.S. stock indexes have been under pressure since …

Wall Street falls for fourth straight day as recession worries overnight Read More »

Wall St rises after CPI data but Fed concerns persist

Consumer prices increase moderately in November Growth, real estate stocks rise as yields fall Moderna leaps on optimistic trial data NEW YORK, Dec 13 (Reuters) – U.S. stocks rose on Tuesday after a surprisingly weak rise in consumer prices boosted optimism that the Federal Reserve may soon reverse its interest rate hikes to rein in …

Wall St rises after CPI data but Fed concerns persist Read More »

S&P 500 ends losing streak on rising jobless claims

Weekly jobless claims rise in line with estimates Moderna and Pfizer in place as FDA clears updated COVID boosters Exxon climbs after strengthening its buyback program Dec 8 (Reuters) – The S&P 500 (.SPX) closed higher on Thursday, ending a five-game losing streak, as investors pushed the index higher after interpreting data showing rising stocks. …

S&P 500 ends losing streak on rising jobless claims Read More »